ABSTRACT
Controlled ovarian hyperstimulation, which is a key component of assisted reproductive technology (ART) treatment, can be excessive in certain cases and can lead to massive cystic enlargement of the ovaries and biochemical changes, leading to ovarian hyperstimulation syndrome (OHSS). Traditionally, human chorionic gonadotropin (hCG) has been used as ovulation trigger in ART cycles but its sustained luteotrophic effect is associated with an increased risk of OHSS in high-risk patients. Gonadotropin-releasing hormone (GnRH) agonist trigger can be used as an alternative to hCG in GnRH antagonist downregulated cycles. However, the use of GnRH agonist was associated with a lower pregnancy rate due to deficient luteal phase, and hence, use of low-dose hCG to rescue the deficient luteal phase has been used. Various studies showed that using lowdose hCG did not increase the risk of OHSS even in high-risk patients. Here, we present a case report of severe early-onset OHSS following GnRH agonist trigger with low-dose hCG.
How to cite this article
Thomas S, Kamath MS, Muthukumar K, Aleyamma TK. Severe Early-onset Ovarian Hyperstimulation Syndrome following Use of GnRH Agonist Trigger along with Low-dose hCG. Int J Infertil Fetal Med 2016;7(2):68-72.
The dual trigger study: Rationale and study design of a prospective double-blind randomized clinical trial comparing pregnancy rates after co-administration of low dose hCG at the time of GnRH agonist trigger or 35 h later for the prevention of OHSS
